Last reviewed · How we verify

Preventative Medication (PM)

NYU Langone Health · FDA-approved active Small molecule

Prevents cardiovascular events by inhibiting platelet aggregation.

Prevents cardiovascular events by inhibiting platelet aggregation. Used for Prevention of cardiovascular events in patients at high risk of heart attack or stroke.

At a glance

Generic namePreventative Medication (PM)
Also known asTopiramate
SponsorNYU Langone Health
Drug classantiplatelet
TargetCOX-1
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Aspirin works by irreversibly inhibiting the enzyme cyclooxygenase-1 (COX-1), which is responsible for the production of thromboxane A2, a potent stimulator of platelet aggregation. This leads to a decrease in the formation of blood clots and a subsequent reduction in the risk of cardiovascular events such as heart attacks and strokes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: